The study will evaluate the Company’s novel mitochondrial DNA-based test for accurately identifying prostate cancer in blood samples from men with elevated PSA levels that are at risk for prostate cancer.
COVID-19 testing service now available from MDNA's UK laboratory: Click here ›
The study will evaluate the Company’s novel mitochondrial DNA-based test for accurately identifying prostate cancer in blood samples from men with elevated PSA levels that are at risk for prostate cancer.